Literature DB >> 29907486

Imaging of Tumor Characteristics and Molecular Pathways With PET: Developments Over the Last Decade Toward Personalized Cancer Therapy.

Loredana Gabriela Marcu1, Leyla Moghaddasi2, Eva Bezak3.   

Abstract

PURPOSE: Improvements in personalized therapy are made possible by the advances in molecular biology that led to developments in molecular imaging, allowing highly specific in vivo imaging of biological processes. Positron emission tomography (PET) is the most specific and sensitive imaging technique for in vivo molecular targets and pathways, offering quantification and evaluation of functional properties of the targeted anatomy.
MATERIALS AND METHODS: This work is an integrative research review that summarizes and evaluates the accumulated current status of knowledge of recent advances in PET imaging for cancer diagnosis and treatment, concentrating on novel radiotracers and evaluating their advantages and disadvantages in cancer characterization. Medline search was conducted, limited to English publications from 2007 onward. Identified manuscripts were evaluated for most recent developments in PET imaging of cancer hypoxia, angiogenesis, proliferation, and clonogenic cancer stem cells (CSC).
RESULTS: There is an expansion observed from purely metabolic-based PET imaging toward antibody-based PET to achieve more information on cancer characteristics to identify hypoxia, proangiogenic factors, CSC, and others. 64Cu-ATSM, for example, can be used both as a hypoxia and a CSC marker.
CONCLUSIONS: Progress in the field of functional imaging will possibly lead to more specific tumor targeting and personalized treatment, increasing tumor control and improving quality of life.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29907486     DOI: 10.1016/j.ijrobp.2018.04.055

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Molecular and functional imaging insights into the role of hypoxia in cancer aggression.

Authors:  Samata Kakkad; Balaji Krishnamachary; Desmond Jacob; Jesus Pacheco-Torres; Eibhlin Goggins; Santosh Kumar Bharti; Marie-France Penet; Zaver M Bhujwalla
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

Review 2.  Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.

Authors:  Circe D van der Heide; Simone U Dalm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-05       Impact factor: 9.236

Review 3.  PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Authors:  Sara S Rinne; Anna Orlova; Vladimir Tolmachev
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

4.  Economical droplet-based microfluidic production of [18F]FET and [18F]Florbetaben suitable for human use.

Authors:  Ksenia Lisova; Jia Wang; Tibor Jacob Hajagos; Yingqing Lu; Alexander Hsiao; Arkadij Elizarov; R Michael van Dam
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

5.  The Exception That Proves the Rule: How Sodium Chelation Can Alter the Charge-Cell Binding Correlation of Fluorescein-Based Multimodal Imaging Agents.

Authors:  Marco Maspero; Clelia Dallanoce; Björn Wängler; Carmen Wängler; Ralph Hübner
Journal:  ChemMedChem       Date:  2022-02-22       Impact factor: 3.540

6.  Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module.

Authors:  Prashanth K Padakanti; Shihong Li; Alexander Schmitz; David Mankoff; Robert H Mach; Hsiaoju S Lee
Journal:  EJNMMI Radiopharm Chem       Date:  2019-03-20

Review 7.  Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.

Authors:  Loredana G Marcu
Journal:  J Pers Med       Date:  2020-11-12

Review 8.  Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer.

Authors:  Richard Yuen; Frederick G West; Frank Wuest
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.